Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

Next Previous
X
Search
Trial Profile

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin; Insulin detemir; Insulin glargine; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms Onset 3
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 05 Oct 2018 Results (n=236) of post-hoc analysis presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
    • 08 Dec 2017 Results of a post-hoc analysis from Onset-2 and Onset-3 studies, presented at the 2017 Congress of the International Diabetes Federation
    • 08 Dec 2017 Results of a post-hoc analysis presented at the 2017 Congress of the International Diabetes Federation.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top